Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial
批准号:
357402
负责人:
Castellucci Lana
金额:
$89.73万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-10-01 至 2021-10-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The presence of new blood clots in the veins of legs and lungs decreases the quality of life of patients and may cause death. After the first clot, patients have higher chances of developing new clots and this increases the possibility of death. The best
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
-
批准号:478040
-
项目类别:Operating Grants
-
资助金额:$46.26万
-
财政年份:2023
-
负责人:Castellucci Lana
-
依托单位:
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
-
批准号:450705
-
项目类别:Operating Grants
-
资助金额:$161.06万
-
财政年份:2021
-
负责人:Castellucci Lana
-
依托单位:
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
-
批准号:432966
-
项目类别:Operating Grants
-
资助金额:$7.29万
-
财政年份:2020
-
负责人:Castellucci Lana
-
依托单位:
海外基金